Journal Article

FZJ-2018-05725

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The Role of Tau Imaging in Parkinsonian Disorders

Hammes, J. (Corresponding author) ; Drzezga, A. ; van Eimeren, T.FZJ*

2018
Current Science Inc. Philadelphia, Pa.

This record in other databases:      

Please use a persistent id in citations: doi:10.1007/s11910-018-0898-3

Abstract: Purpose of ReviewDifferential diagnosis of atypical Parkinson syndromes (APS) is difficult as clinical presentations may vary and as there is a strong overlap between disease entities. Aggregations of misfolded and hyperphosphorylated tau proteins are the common denominator of many of these diseases.Recent FindingsSeveral tau targeting positron emission tomography (PET) tracers have been evaluated as possible biomarkers in APS in the recent years. For Parkinson’s disease, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration, promising results have been reported with regard to the ability to detect the presence of disease and to discriminate patients from controls. However, the discussion about the specificity of the first-generation radiotracers and their value in the clinical context is ongoing.SummaryA combined interpretation of signal strength and distribution pattern in PET scans with first- and second-generation tracers may be helpful in clinical diagnosis and follow-up of patients with APS

---

Contributing Institute(s):

1. Kognitive Neurowissenschaften (INM-3)

Research Program(s):

1. 572 - (Dys-)function and Plasticity (POF3-572) (POF3-572)

Appears in the scientific report 2018

---

Database coverage:
; Clarivate Analytics Master Journal List ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---